24 Jul 2019 --- Swiss chemicals and biotechnology company Lonza has reported a “continued positive momentum” for its core healthcare businesses for the first half of 2019. The company says that it is “on track” with its goals and that the half-year results translate into a 6.4 percent sales and 7.7 percent CORE EBITDA growth. This has resulted in a CORE EBITDA margin of 27.8 percent. The half-year performance was driven by Lonza’s Pharma Biotech & Nutrition (LPBN) segment achieving 10.8 percent sales growth and a 33.2 percent CORE EBITDA margin in an important investment year, the company notes.
